Ratings by Evercore ISI (Maneka Mirchandaney)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/12/2024 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2023 | Crinetics | CRNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2023 | Incyte | INCY | Maintain | In Line (N/A) |
|
Details | ||
| 4/10/2023 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2023 | MiNK Therapeutics | INKT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2023 | Seagen | SGEN | Downgrade | In Line (Outperform) |
172.61 (228.74) |
32.52% | Details | |
| 3/10/2023 | Bionomics Ltd. | BNOX | Upgrade | Outperform (In Line) |
4.65 (0.98) |
-78.92% | Details | |
| 2/16/2023 | Seagen | SGEN | Upgrade | Outperform (In Line) |
140.82 (228.74) |
62.43% | Details | |
| 2/7/2023 | Incyte | INCY | Maintain | In Line (N/A) |
|
Details | ||
| 12/20/2022 | Bionomics Ltd. | BNOX | Downgrade | In Line (Outperform) |
6.80 (0.98) |
-85.59% | Details | |
| 11/1/2022 | Incyte | INCY | Maintain | In Line (N/A) |
|
Details | ||
| 8/15/2022 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Incyte | INCY | Downgrade | In Line (N/A) |
72.58 (53.43) |
-26.38% | Details | |
| 1/10/2022 | Bionomics Ltd. | BNOX | New Coverage | Outperform (N/A) |
11.55 (0.98) |
-91.52% | Details | |
| 11/23/2021 | Crinetics | CRNX | New Coverage | Outperform (N/A) |
26.49 (43.68) |
64.89% | Details | |
| 11/9/2021 | MiNK Therapeutics | INKT | New Coverage | Outperform (N/A) |
18.96 (0.91) |
-95.2% | Details | |
| 11/2/2021 | Incyte | INCY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/12/2021 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
15.65 (15.64) |
-0.06% | Details | |
| 5/25/2021 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Outperform (N/A) |
12.18 (5.49) |
-54.93% | Details | |
| 5/17/2021 | Seagen | SGEN | New Coverage | In Line (N/A) |
147.50 (228.74) |
55.08% | Details | |
| 7/29/2020 | Principia Biopharma | PRNB | New Coverage | Outperform (N/A) |
88.65 (100.05) |
12.86% | Details |
